CERS
Price
$3.09
Change
-$0.03 (-0.96%)
Updated
Jul 13 closing price
Capitalization
619.14M
16 days until earnings call
Intraday BUY SELL Signals
STXS
Price
$1.64
Change
-$0.06 (-3.53%)
Updated
Jul 13 closing price
Capitalization
163.07M
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CERS vs STXS

CERS vs STXS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CERS vs. STXS commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and STXS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (CERS: $3.09 vs. STXS: $1.64)
Brand notoriety: CERS and STXS are both not notable
CERS represents the Medical/Nursing Services, while STXS is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CERS: 29% vs. STXS: 130%
Market capitalization -- CERS: $619.14M vs. STXS: $163.07M
CERS [@Medical/Nursing Services] is valued at $619.14M. STXS’s [@Pharmaceuticals: Other] market capitalization is $163.07M. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $160.44B to $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $144.19B to $0. The average market capitalization across the [@Medical/Nursing Services] industry is $5.64B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $7.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileSTXS’s FA Score has 0 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • STXS’s FA Score: 0 green, 5 red.
According to our system of comparison, CERS is a better buy in the long-term than STXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 3 TA indicator(s) are bullish while STXS’s TA Score has 3 bullish TA indicator(s).

  • CERS’s TA Score: 3 bullish, 5 bearish.
  • STXS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CERS is a better buy in the short-term than STXS.

Price Growth

CERS (@Medical/Nursing Services) experienced а -5.79% price change this week, while STXS (@Pharmaceuticals: Other) price change was -13.23% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +7.62%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -16.57%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.39%. For the same industry, the average monthly price growth was +7.29%, and the average quarterly price growth was -8.66%.

Reported Earning Dates

CERS is expected to report earnings on Jul 30, 2026.

STXS is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Medical/Nursing Services (+7.62% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

@Pharmaceuticals: Other (-2.39% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($619M) has a higher market cap than STXS($163M). CERS YTD gains are higher at: 50.000 vs. STXS (-28.696). CERS has higher annual earnings (EBITDA): 475K vs. STXS (-20.58M). CERS has more cash in the bank: 80.4M vs. STXS (14.6M). STXS has less debt than CERS: STXS (5.28M) vs CERS (97.4M). CERS has higher revenues than STXS: CERS (217M) vs STXS (31.2M).
CERSSTXSCERS / STXS
Capitalization619M163M380%
EBITDA475K-20.58M-2%
Gain YTD50.000-28.696-174%
P/E RatioN/AN/A-
Revenue217M31.2M696%
Total Cash80.4M14.6M551%
Total Debt97.4M5.28M1,845%
FUNDAMENTALS RATINGS
CERS vs STXS: Fundamental Ratings
CERS
STXS
OUTLOOK RATING
1..100
3469
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
98
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
3675
P/E GROWTH RATING
1..100
10058
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (35) in the Medical Specialties industry is somewhat better than the same rating for STXS (98). This means that CERS’s stock grew somewhat faster than STXS’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STXS (100). This means that CERS’s stock grew similarly to STXS’s over the last 12 months.

CERS's SMR Rating (96) in the Medical Specialties industry is in the same range as STXS (100). This means that CERS’s stock grew similarly to STXS’s over the last 12 months.

CERS's Price Growth Rating (36) in the Medical Specialties industry is somewhat better than the same rating for STXS (75). This means that CERS’s stock grew somewhat faster than STXS’s over the last 12 months.

STXS's P/E Growth Rating (58) in the Medical Specialties industry is somewhat better than the same rating for CERS (100). This means that STXS’s stock grew somewhat faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSSTXS
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 12 days ago
76%
Bullish Trend 8 days ago
76%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
CERS
Daily Signal:
Gain/Loss:
STXS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCLAX66.56N/A
N/A
Fidelity Advisor Industrials A
PRACX53.52N/A
N/A
Putnam U.S. Research C
MSCFX37.65N/A
N/A
Mairs & Power Small Cap
JNBZX10.89N/A
N/A
JPMorgan Income Builder R6
AXVNX22.07N/A
N/A
Acclivity Small Cap Value N

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
-3.53%
SMTI - STXS
38%
Loosely correlated
+4.62%
TWST - STXS
36%
Loosely correlated
-0.31%
CERS - STXS
35%
Loosely correlated
-0.96%
BLFS - STXS
35%
Loosely correlated
-0.28%
RGEN - STXS
33%
Loosely correlated
+0.44%
More